Senl-206

N/A

Report date: 2024/07/23 17:59:06

Base Information

Drug NameSenl-206
Drug Alias NameSenl-206
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-IL13RA2
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsAnti-Glomerular Basement Membrane Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsAnti-Glomerular Basement Membrane Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A